Sympathetic dystrophy associated with sirolimus therapy.

Sympathetic dystrophy associated with sirolimus therapy.

Item
http://www.wikidata.org/entity/Q46796347
Adenosine Monophosphate-activated Protein Kinase (AMPK) Activators For the Prevention, Treatment and Potential Reversal of Pathological Pain.The pros and the cons of mTOR inhibitors in kidney transplantation.mTORC1 inhibition induces pain via IRS-1-dependent feedback activation of ERK.Complex regional pain syndrome type I of the knee: a systematic literature review.Late onset tacrolimus-induced life-threatening polyneuropathy in a kidney transplant recipient patient.Activation of the Mammalian Target of Rapamycin in the Rostral Ventromedial Medulla Contributes to the Maintenance of Nerve Injury-Induced Neuropathic Pain in RatEverolimus: efficacy and safety in cardiac transplantation.Targeting AMPK for the Alleviation of Pathological Pain.No major neurologic complications with sirolimus use in heart transplant recipients.Rapamycin exacerbates cardiovascular dysfunction after complete high-thoracic spinal cord injury.
P2860

Sympathetic dystrophy associated with sirolimus therapy.

Item
http://www.wikidata.org/entity/Q46796347
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
Sympathetic dystrophy associated with sirolimus therapy.
@en
Sympathetic dystrophy associated with sirolimus therapy.
@nl
type
label
Sympathetic dystrophy associated with sirolimus therapy.
@en
Sympathetic dystrophy associated with sirolimus therapy.
@nl
prefLabel
Sympathetic dystrophy associated with sirolimus therapy.
@en
Sympathetic dystrophy associated with sirolimus therapy.
@nl
P1433
P1476
P2093
P304
P31
P356
P433
P478
P50
P577
P698
P356
P1433
P1476
Sympathetic dystrophy associated with sirolimus therapy.
@en
P2093
P304
P31
P356
10.1097/TP.0B013E3181601230
P433
P478
P50
P577
P698